The double-blind, placebo-controlled clinical study is designed to assess the safety, tolerability and pharmacokinetics of a subcutaneous injection of PulmoLar.
PulmoLar is PRP’s proprietary sustained-release injectable formulation of the active ingredient 2ME, a compound which has multiple mechanisms of action, many of which are relevant to pulmonary arterial hypertension (PAH). In vitro studies have demonstrated 2ME reduces endothelial cell production of endothelin-1 and increases synthesis of prostacyclin.
“It is very gratifying to see our collaborative efforts with PRP come to fruition as PulmoLar enters the clinical phase of development. We’re optimistic that PulmoLar may provide significant therapeutic benefits in the treatment of PAH, a devastating disease for which additional therapies are desperately needed,” said Dr Stevan Tofovic assistant professor at the University of Pittsburgh School of Medicine and key investigator/inventor on the use of 2ME for PAH.